Upgrade to SI Premium - Free Trial

Truist Securities Downgrades Fulcrum Therapeutics (FULC) to Hold

June 2, 2026 1:04 AM
Truist Securities analyst Gregory Renza downgraded Fulcrum Therapeutics (NASDAQ: FULC) from Buy to Hold with a price target of $4.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Downgrades